Rostafuroxin

Structural formula
General
Non-proprietary name	Rostafuroxin
other names	21,23-epoxy-24-nor-14 β , 5 β -chola-20,21-diene-3 β , 14,17 α -triol
Molecular formula	C 23 H 34 O 4
External identifiers / databases
PubChem	153976
ChemSpider	135709
DrugBank	DB12350
Wikidata	Q1110424
properties
Molar mass	374.52 g mol −1
safety instructions
GHS hazard labeling ; no classification available
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Rostafuroxin (PST 2238) is a digitoxigenin - derivative serving as an antagonist of ouabain ( ouabain competitive) it from the Na ⁺ / K ⁺ -ATPase displaced.

The use of rostafuroxin was expected to be positive in chronic arterial hypertension , but in 2011 5 double-blind, crossover phase II studies in 410 hypertensive patients with (140-169 mm Hg) did not show any antihypertensive effects at any of the doses tested.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ Staessen, YES. and Bianchi, G. (2005): Adducin and hypertension . In: Pharmacogenomics 6 (7); 665-9; PMID 16207143 ; PDF (free full text access).
↑ Manunta, P. (2001): A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin. In: Cardiovasc. Hematol. Agents. Med. Chem. Vol. 4, pp. 61-66, PMID 16529550 .
↑ JA Staessen, L. Thijs u. a .: Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. In: Trials. Volume 12, January 2011, p. 13, doi : 10.1186 / 1745-6215-12-13 , PMID 21235787 , PMC 3031200 (free full text).

Web links

Ferrari, P. et al. (1998): PST2238: a new antihypertensive compound that antagonizes the long-term pressor effect of ouabain . In: J Pharmacol Exp Ther. 285 (1); 83-94; PMID 9535997 ; PDF (free full text access)
Iwamoto, T. and Kita, S. et al. (2006): Hypertension, Na + / Ca2 + exchanger, and Na +, K + -ATPase . In: Kidney Int . 69 (12); 2148-54; PMID 16641927

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[Staessen-2] Staessen, YES. and Bianchi, G. (2005): Adducin and hypertension . In: Pharmacogenomics 6 (7); 665-9; PMID 16207143 ; PDF (free full text access).

[3] Manunta, P. (2001): A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin. In: Cardiovasc. Hematol. Agents. Med. Chem. Vol. 4, pp. 61-66, PMID 16529550 .

[PMID21235787-4] JA Staessen, L. Thijs u. a .: Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin. In: Trials. Volume 12, January 2011, p. 13, doi : 10.1186 / 1745-6215-12-13 , PMID 21235787 , PMC 3031200 (free full text).